Study of Anti-Müllerian Hormone and Its Relation to the Subsequent Probability of Pregnancy in 112 Patients With Systemic Lupus Erythematosus, Exposed or Not to Cyclophosphamide

摘要: CONTEXT: Cyclophosphamide is used for renal and major extrarenal involvement in systemic lupus erythematosus (SLE) associated with a risk of premature ovarian failure. There are no data available about the relation between anti-Mullerian hormone (AMH) serum levels probability subsequent pregnancy SLE patients. OBJECTIVE: We analyzed AMH women exposed to cyclophosphamide. DESIGN AND SETTING: conducted matched cohort study referral centers SLE. PATIENTS: Fifty-six cyclophosphamide-exposed younger than 40 years age 56 control within 6 months participated study. MAIN OUTCOME MEASURES: was measured samples from PLUS (ClinicalTrials.gov no. NCT00413361). All patients were interviewed May 2012 regarding their obstetric status. RESULTS: The mean ± SD 112 31.6 5.8 years. level low (1.21 1.01 ng/mL) significantly lower cyclophosphamide (P = .03) older 30 .02). During median follow-up (interval sampling interview) period 4.2 (range, 2.5-4.8) years, 38 sought become pregnant, 32 (84.2%) succeeded. In univariate analysis, failure cumulative dose .007) .02), but not AMH. CONCLUSION: confirmed that decrease exposure. Nonetheless, conceive predicted by exposure age, levels.